Proteon Therapeutics wins $45 million financing round

05/19/2014 10:24 AM

06/03/2014 10:17 AM

Proteon Therapeutics, a biotechnology firm founded in Kansas City, has obtained $45 million in equity financing that includes $25 million to proceed with a Phase III clinical trial.

The privately owned firm, now based in Waltham, Mass., has developed a drug designed to reduce blood vessel blockage in dialysis patients who have chronic kidney disease.

Blockage is a common problem for people who have had surgery to create a dialysis access site known as an arteriovenous fistula.

The drug, PRT-201, has been in development for a decade. Proteon was founded in 2001 by Nicholas Franano and Bill Whitaker, who launched the enterprise with $50,000.

Novartis AG, a pharmaceutical giant, had considered but declined to exercise a $550 million option agreement to buy Proteon this year.

The new financing round was led by Abingworth LLP, an investment group focused on life science and health care firms.

Other participants were Deerfield Management Co., an investment management firm; and Pharmstandard International S.A., a holding company by OJSC Pharmstandard.

Also included were existing investors TVM Capital; Prism VentureWorks, Skyline Ventures, Intersouth Partners, MPM Capital, Devon Park Bioventures, Bessemer Venture Partners, and Vectis Healthcare and Life Sciences Fund.

To reach Diane Stafford, call 816-234-4359 or send email to


Join the Discussion

The Kansas City Star is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere on the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Terms of Service